BTMD

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 3.67 USD with a low forecast of 3.00 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biote Corp revenue for the last quarter amounts to 47.96M USD, decreased -6.67 % YoY.

Biote Corp. EPS for the last quarter amounts to 0.22 USD, decreased -33.33 % YoY.

Biote Corp (BTMD) has 217 emplpoyees as of December 15 2025.

Today BTMD has the market capitalization of 123.29M USD.